Akari Q3: $5.7M Cash, GLP Tox Started for AKTX-101, Phase 1 Targeted Mid-2027
AKTX has more than doubled off its 52-week low of $3.015 on light trading volume (0.2× avg).
Summary
Akari's Q3 release confirms $5.7M of cash and roughly $2.9M raised from warrant exercises, while disclosing that GLP toxicology for AKTX-101 has begun and new preclinical data show activity in tumors resistant to existing ADCs. The Phase 1 is still targeted for mid-2027 and still depends on additional financing.
Key Events · Earnings and Guidance · AKTX
-
GLP Toxicology Started for AKTX-101
Akari has initiated GLP toxicology studies for its lead TROP2-targeted ADC and continues IND-enabling non-clinical and CMC work toward a Phase 1 in mid-2027, subject to obtaining additional financing.
-
Preclinical Activity in Resistant Tumors
In the UM-UC-14 urothelial model, where Padcev showed limited activity, AKTX-101 produced statistically significant tumor growth inhibition versus vehicle; it also slowed growth of Trodelvy-resistant tumors after switching to AKTX-101.
-
Q3 Cash $5.7M After Warrant Proceeds
Cash stood at $5.7M at quarter-end versus $5.2M at December 31, 2025, after roughly $2.9M of warrant exercise proceeds; the $0.7M of convertible notes were repaid in full at the August 31, 2026 maturity, leaving no notes outstanding.
-
Q3 Loss Narrows to $4.8M
Operating expenses fell to $4.7M from $7.4M a year earlier, a prior-year quarter that included a $5.2M impairment on the former PHP-303 program; R&D rose to $2.1M from $0.2M while G&A rose to $2.6M from $2.0M. Net loss was $4.8M versus $6.4M.
Analysis · AKTX · Life Sciences
The Q3 numbers were already out via the same-day 10-Q, so the financials are not the news. What is new is the operating detail: Akari has started GLP toxicology for its lead TROP2 ADC AKTX-101, reported preclinical activity in urothelial models where Padcev had limited effect and in tumors that had grown resistant to Trodelvy, and filed an international patent application on the PH1 splicing mechanism. Against that progress sits $5.7M of cash and a Phase 1 planned for mid-2027 that the company itself says is subject to raising more money — the program is advancing on a balance sheet that cannot fund it to the trial start without new capital.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKTX was trading at $6.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $3.02 to $29.32. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.